Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ayala Pharmaceuticals Inc (ADXS)

Ayala Pharmaceuticals Inc (ADXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ayala Pharmaceuticals Inc 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852 USA

www.ayalapharma.com P: 609-452-9813

Description:

Ayala Pharmaceuticals Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. It also involved in developing proprietary Lm-based antigen delivery products for patients suffering from more common cancers. The company's lead candidates under development are AL102 and ADXS-504. Ayala Pharmaceuticals Inc., formerly known as Advaxis Inc., is based in REHOVOT, Israel.

Key Statistics

Overview:

Market Capitalization, $K 6,462
Enterprise Value, $K 4,342
Shares Outstanding, K 10,752
Annual Sales, $ 253 K
Annual Net Income, $ -26,469 K
Last Quarter Sales, $ 10 K
Last Quarter Net Income, $ -8,700 K
EBIT, $ -25,210 K
EBITDA, $ -25,070 K
60-Month Beta 1.62
% of Insider Shareholders 0.63%
% of Institutional Shareholders 7.18%
Float, K 10,684
% Float 99.37%
Short Volume Ratio 0.02

Growth:

1-Year Return -47.94%
3-Year Return -98.33%
5-Year Return -99.77%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.53 on 11/20/23
Latest Earnings Date 02/19/24
Earnings Per Share ttm -3.49
EPS Growth vs. Prev Qtr 15.93%
EPS Growth vs. Prev Year -65.01%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-80 on 06/06/22

ADXS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -10,462.06%
Debt/Equity 0.00
Price/Sales 8.16
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.21
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar